Q1 FY27 results: PAT drops 52% YoY to Rs 3.98 cr on margin pressure

Ebitda Margin CompressionExceptional ItemResults View source PDF Explain this filing

AMBALALSA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-8.3%Reaction day

₹44.72

prior close

₹42.80

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.2%-8.5% vs market

Pharmaceuticals peers, median of 166sector+0.1%-8.4% vs sector

On the reaction day the stock moved 8.5 pts less than Nifty Microcap 250 and 8.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.6

10m

-0.7

15m

-2.7

30m

-3.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-8.3+0.2-8.5+0.1-8.4

Next day

-6.1+0.2-6.3-0.2-5.9

+2.2+0.4+1.8-0.2+2.4

+7.0+0.7+6.3-0.4+7.5

+4.4+0.1+4.3-1.5+5.9

+8.0+0.7+7.3-0.9+8.8

-1.6+1.2-2.8-0.5-1.1

15d

-2.4+0.7-3.2+0.3-2.8

-13.2-1.2-12.0-0.0-13.2

-13.9-1.1-12.8-2.3-11.7

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Ambalal Sarabhai Enterprises posted Q1 FY27 consolidated results: revenue from operations rose 8 percent YoY to Rs 43.56 crore, but net profit fell 52 percent to Rs 3.98 crore versus Rs 8.22 crore last year. Pharma segment results nearly halved to Rs 4.38 crore from Rs 8.38 crore. Electronics revenue grew 23 percent to Rs 18.33 crore. Standalone PAT collapsed to Rs 3 lakh from Rs 6.88 crore. Auditor issued an unqualified review report.

Likely market impact

Sharp fall in profitability despite top-line growth, mainly in pharma segment and lower other income, may weigh on the stock near term.